High-temperature-required Protein A2 As a Predictive Marker for Response to Chemotherapy and Prognosis in Patients with High-grade Serous Ovarian Cancers

Overview

Journal Br J Cancer

Specialty Oncology

Date 2015 Jan 29

PMID 25628093

Citations 8

Authors

M Miyamoto

M Takano

K Iwaya

N Shinomiya

T Goto

M Kato

A Suzuki

T Aoyama

J Hirata

I Nagaoka

H Tsuda

K Furuya

Affiliations

Soon will be listed here.

Abstract

Background: High-temperature-required protein A2 (HtrA2), a protein relating with apoptosis in a caspases-dependent and non-dependent manner, has been reported to be associated with chemosensitivity in several human cancers.

Methods: Tissue microarrays made from 142 patients with high-grade serous ovarian adenocarcinoma were evaluated to assess whether HtrA2 expression was related with several clinical parameters.

Results: Negative HtrA2 expression was observed in 36 cases (25%) of the patients, and related with significantly lower response rates of primary chemotherapy than those with positive HtrA2 expression (56% vs 83%, P<0.01). In addition, negative HtrA2 expression was identified as an independent worse prognostic factor for progression-free survival and overall survival by multivariate analyses. Furthermore, HtrA2 downregulation modulated sensitivity to platinum in serous ovarian cancer cells in vitro.

Conclusions: HtrA2 expression was a predictor for sensitivity to chemotherapy, and could be a candidate of molecular target in the treatment of high-grade serous ovarian cancers.

Citing Articles

HtrA2 Independently Predicts Poor Prognosis and Correlates with Immune Cell Infiltration in Hepatocellular Carcinoma.

Feng L, Li Z, Xiong Y, Yan T, Fu C, Zeng Q J Oncol. 2023; 2023:4067418.

PMID: 36704205 PMC: 9873461. DOI: 10.1155/2023/4067418.

Clinical significance of CD8-positive lymphocytes on tumor cell clusters of ascites cell block in ovarian high-grade serous carcinoma.

Iwahashi H, Miyamoto M, Ito T, Suminokura J, Hada T, Ishibashi H Cancer Med. 2022; 11(10):2085-2095.

PMID: 35137571 PMC: 9119359. DOI: 10.1002/cam4.4592.

mRNA microarray profiling identifies a novel circulating HTRA2 for detection of gastric cancer.

Wu L, Li X, Chen X, Wu F, Sun G, Cheng Y J Clin Lab Anal. 2021; 35(12):e24054.

PMID: 34708890 PMC: 8649374. DOI: 10.1002/jcla.24054.

Expression of HTRA Genes and Its Association with Microsatellite Instability and Survival of Patients with Colorectal Cancer.

Zurawa-Janicka D, Kobiela J, Slebioda T, Peksa R, Stanislawowski M, Wierzbicki P Int J Mol Sci. 2020; 21(11).

PMID: 32486357 PMC: 7312515. DOI: 10.3390/ijms21113947.

The expression of HtrA2 and its diagnostic value in patients with hepatocellular carcinoma.

Wang H, Jiang F, Hao F, Ju R Medicine (Baltimore). 2018; 97(14):e0128.

PMID: 29620624 PMC: 5902255. DOI: 10.1097/MD.0000000000010128.

References

Cannistra S . Cancer of the ovary. N Engl J Med. 2004; 351(24):2519-29. DOI: 10.1056/NEJMra041842. View

Chien J, Aletti G, Baldi A, Catalano V, Muretto P, Keeney G . Serine protease HtrA1 modulates chemotherapy-induced cytotoxicity. J Clin Invest. 2006; 116(7):1994-2004. PMC: 1474818. DOI: 10.1172/JCI27698. View

Therasse P, Arbuck S, Eisenhauer E, Wanders J, Kaplan R, Rubinstein L . New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92(3):205-16. DOI: 10.1093/jnci/92.3.205. View

Suzuki Y, Takahashi-Niki K, Akagi T, Hashikawa T, Takahashi R . Mitochondrial protease Omi/HtrA2 enhances caspase activation through multiple pathways. Cell Death Differ. 2003; 11(2):208-16. DOI: 10.1038/sj.cdd.4401343. View

Izeradjene K, Douglas L, Delaney A, Houghton J . Casein kinase I attenuates tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by regulating the recruitment of fas-associated death domain and procaspase-8 to the death-inducing signaling complex. Cancer Res. 2004; 64(21):8036-44. DOI: 10.1158/0008-5472.CAN-04-0762. View

Kikuchi Y, Miyauchi M, Kizawa I, Oomori K, Kato K . Establishment of a cisplatin-resistant human ovarian cancer cell line. J Natl Cancer Inst. 1986; 77(6):1181-5. View

Clausen T, Southan C, Ehrmann M . The HtrA family of proteases: implications for protein composition and cell fate. Mol Cell. 2002; 10(3):443-55. DOI: 10.1016/s1097-2765(02)00658-5. View

Narkiewicz J, Klasa-Mazurkiewicz D, Zurawa-Janicka D, Skorko-Glonek J, Emerich J, Lipinska B . Changes in mRNA and protein levels of human HtrA1, HtrA2 and HtrA3 in ovarian cancer. Clin Biochem. 2008; 41(7-8):561-9. DOI: 10.1016/j.clinbiochem.2008.01.004. View

Wang C, Lin Y, Su W, Chen C, Lin C . Glycogen synthase kinase-3 and Omi/HtrA2 induce annexin A2 cleavage followed by cell cycle inhibition and apoptosis. Mol Biol Cell. 2009; 20(19):4153-61. PMC: 2754929. DOI: 10.1091/mbc.e09-02-0174. View

10.

Hu S, Carozza M, Klein M, Nantermet P, Luk D, Crowl R . Human HtrA, an evolutionarily conserved serine protease identified as a differentially expressed gene product in osteoarthritic cartilage. J Biol Chem. 1998; 273(51):34406-12. DOI: 10.1074/jbc.273.51.34406. View

11.

Chien J, Staub J, Hu S, Erickson-Johnson M, Couch F, Smith D . A candidate tumor suppressor HtrA1 is downregulated in ovarian cancer. Oncogene. 2004; 23(8):1636-44. DOI: 10.1038/sj.onc.1207271. View

12.

Inagaki A, Nishizawa H, Ota S, Suzuki M, Inuzuka H, Miyamura H . Upregulation of HtrA4 in the placentas of patients with severe pre-eclampsia. Placenta. 2012; 33(11):919-26. DOI: 10.1016/j.placenta.2012.08.003. View

13.

Takano M, Tsuda H, Sugiyama T . Clear cell carcinoma of the ovary: is there a role of histology-specific treatment?. J Exp Clin Cancer Res. 2012; 31:53. PMC: 3405444. DOI: 10.1186/1756-9966-31-53. View

14.

Lipinska B, Zylicz M, Georgopoulos C . The HtrA (DegP) protein, essential for Escherichia coli survival at high temperatures, is an endopeptidase. J Bacteriol. 1990; 172(4):1791-7. PMC: 208670. DOI: 10.1128/jb.172.4.1791-1797.1990. View

15.

Sasa H, Hisano A, Ishii K, Hirata J, Kikuchi Y, Nagata I . [Establishment of a cisplatin-resistant human ovarian cancer cell line]. Hum Cell. 1993; 6(2):106-13. View

16.

Zurawa-Janicka D, Jarzab M, Polit A, Skorko-Glonek J, Lesner A, Gitlin A . Temperature-induced changes of HtrA2(Omi) protease activity and structure. Cell Stress Chaperones. 2012; 18(1):35-51. PMC: 3508124. DOI: 10.1007/s12192-012-0355-1. View

17.

Yang X, Xing H, Gao Q, Chen G, Lu Y, Wang S . Regulation of HtrA2/Omi by X-linked inhibitor of apoptosis protein in chemoresistance in human ovarian cancer cells. Gynecol Oncol. 2005; 97(2):413-21. DOI: 10.1016/j.ygyno.2004.12.055. View

18.

Faccio L, Fusco C, Chen A, Martinotti S, Bonventre J, Zervos A . Characterization of a novel human serine protease that has extensive homology to bacterial heat shock endoprotease HtrA and is regulated by kidney ischemia. J Biol Chem. 2000; 275(4):2581-8. DOI: 10.1074/jbc.275.4.2581. View

19.

Singh H, Li Y, Fuller P, Harrison C, Rao J, Stephens A . HtrA3 Is Downregulated in Cancer Cell Lines and Significantly Reduced in Primary Serous and Granulosa Cell Ovarian Tumors. J Cancer. 2013; 4(2):152-64. PMC: 3572407. DOI: 10.7150/jca.5702. View

20.

Kaminskyy V, Piskunova T, Zborovskaya I, Tchevkina E, Zhivotovsky B . Suppression of basal autophagy reduces lung cancer cell proliferation and enhances caspase-dependent and -independent apoptosis by stimulating ROS formation. Autophagy. 2012; 8(7):1032-44. PMC: 3429541. DOI: 10.4161/auto.20123. View